Last update 25 Mar 2025

Carisbamate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Carisbamate (USAN), Comfyde, JNJ-10234094
+ [3]
Action
modulators
Mechanism
Neurotransmitter receptor modulators
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H10ClNO3
InChIKeyOLBWFRRUHYQABZ-MRVPVSSYSA-N
CAS Registry194085-75-1

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EpilepsyNDA/BLA
United States
-
EpilepsyNDA/BLA
European Union
-
Langer-Giedion SyndromePhase 3
United States
28 Apr 2022
Langer-Giedion SyndromePhase 3
Argentina
28 Apr 2022
Langer-Giedion SyndromePhase 3
Australia
28 Apr 2022
Langer-Giedion SyndromePhase 3
Colombia
28 Apr 2022
Langer-Giedion SyndromePhase 3
Germany
28 Apr 2022
Langer-Giedion SyndromePhase 3
Greece
28 Apr 2022
Langer-Giedion SyndromePhase 3
Hungary
28 Apr 2022
Langer-Giedion SyndromePhase 3
Israel
28 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
11
Placebo
(Placebo)
ptzwstonqu(cqbkzzrwoh) = tiqmlzjhdz eyicaqesoq (adqtxaieft, 7.1)
-
02 Mar 2021
(Carisbamate)
ptzwstonqu(cqbkzzrwoh) = yrlqzetwyt eyicaqesoq (adqtxaieft, 7.6)
Phase 3
547
kkxslkvsta(tgprdtahnf) = Dizziness was the most common treatment-emergent adverse event, with a higher incidence (≥ 5% difference) in the combined carisbamate group (31%) than placebo (9%); the incidence was higher with carisbamate 1,200 mg (32%, n = 58) than with carisbamate 800 mg (30%, n = 53) mviarlyggn (mdhhwbtdll )
Negative
01 Apr 2011
Not Applicable
419
utkvlnnnrm(kasmqlmpza) = low behavioral/psychiatric adverse event rates tvtnakojff (tdvwrrowqm )
Positive
02 Jul 2009
Not Applicable
-
qlckalngfs(zpfliszxdi) = low behavioral/psychiatric adverse event rates mmmuuxvaxv (sxirxgstws )
Positive
02 Jul 2009
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free